Abstract: The present invention relates to a glycol chitosane derivative, a preparation method thereof and a drug delivery system comprising the same. More specifically, the invention relates to a glycol chitosan derivative, which can form nano-sized self-assembled structures and has both temperature sensitivity and biodegradability so as to be suitable for use as a drug delivery system, as well as a preparation method thereof and a drug delivery system comprising the same.
Type:
Grant
Filed:
December 21, 2010
Date of Patent:
May 21, 2013
Assignee:
Chungnam National University Collaboration Foundation
Abstract: This invention relates to a fulvic acid and antibiotic combination for use in the treatment of various diseases and conditions. The invention further relates to the use of the combination for the treatment of various diseases and conditions, including bacterial infection. In particular, the bacteria are antibiotic resistant bacteria.
Type:
Grant
Filed:
June 4, 2009
Date of Patent:
May 21, 2013
Assignee:
Pfeinsmith Ltd.
Inventors:
Antonio Celestino Fernandes, Constance Elizabeth Medlen, Stephen Leivers
Abstract: Provided herein are ginsenoside compositions comprising at least 10% (w/w) of a protopanaxadiol type of ginsenoside suitable for administration to a subject. Also provided are methods using the ginsenoside compositions for reducing acetaldehyde concentrations, preventing or ameliorating a symptom of elevated acetaldehyde concentration, or reducing the risk of diseases or disorders caused by the intake of ethyl alcohol.
Abstract: Methods for treating disease states in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide are provided. Methods for alleviating the symptoms of a disease state in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide in the subject are also provided. Pharmaceutical compositions comprising cobinamide and a pharmaceutically acceptable carrier are also provided.
Type:
Grant
Filed:
June 17, 2005
Date of Patent:
April 30, 2013
Assignee:
The Regents of the University of California
Inventors:
Gerry Boss, Vijay Sharma, Kate E. Broderick
Abstract: The present invention provides compounds characterized by the formula (I), where each of the substituent radicals is described in the specification. The invention also describes the use of said compounds in the treatment of various diseases, including: cancer or tumoral processes in general, Paget's disease, hypercalcaemia, hypercalciuria and neurological diseases (inter alia, Parkinson's, Alzheimer's, Huntington's).
Type:
Grant
Filed:
February 4, 2008
Date of Patent:
April 23, 2013
Assignees:
University of Kentucky Research Foundation, Universidad de Oviedo
Inventors:
Jürgen Rohr, Irfan Baig, José Antonio Salas Fernández, Alfredo Fernández Braña, Carmen Méndez Fernández, Mariá Pérez Solares
Abstract: The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.
Type:
Grant
Filed:
October 29, 2010
Date of Patent:
April 16, 2013
Assignee:
Reliable Biopharmaceutical Corporation
Inventors:
Payal Parth Patel, Chun Ma, Kevin K. Ohrr, Sourena Nadji
Abstract: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
Abstract: The invention relates to antibiotic macrolides of formula (I), which have improved anti-inflammatory activity mediated through inhibition of phosphodiesterase 4 (PDE4) useful for the treatment and/or prevention of inflammatory, allergic and proliferative diseases.
Type:
Grant
Filed:
February 9, 2009
Date of Patent:
April 2, 2013
Assignee:
Basilea Pharmaceutica AG
Inventors:
Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Z1, Z2, Z3, Z4, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Type:
Grant
Filed:
March 9, 2011
Date of Patent:
March 19, 2013
Assignee:
Achaogen, Inc.
Inventors:
James Bradley Aggen, Martin Sheringham Linsell, Adam Aaron Goldblum, Darin James Hildebrandt, Timothy Robert Kane, Paola Dozzo, Micah James Gliedt, Stephen Hanessian, Alexandre Giguère, Justyna Grzyb, Juan Pablo Maianti
Abstract: Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide.
Type:
Grant
Filed:
November 10, 2009
Date of Patent:
March 12, 2013
Assignee:
Allergan, Inc.
Inventors:
Dimitrios Stroumpoulis, Dustin B. Leslie, Christopher S. Mudd, Ahmet Tezel
Abstract: Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide.
Type:
Grant
Filed:
April 4, 2012
Date of Patent:
March 12, 2013
Assignee:
Allergan, Inc.
Inventors:
Dimitrios Stroumpoulis, Dustin Leslie, Christopher S. Mudd, Ahmet Tezel
Abstract: Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide. In some embodiments, the incorporating step comprises 1) mixing the at least one inhibitor with the at least one polysaccharide at a highly hydrated state thereby encapsulating the at least one inhibitor in a polysaccharide network, and 2) dehydrating the polysaccharide network thereby controlling release kinetics or final swell ratio. In another embodiment, the incorporating step comprises 1) encapsulating at least one inhibitor into a biocompatible or biodegradable vessel and 2) combining the polysaccharide and the vessel into a gel formulation. The polysaccharide gel formulations described herein can be used for a variety of cosmetic applications.
Type:
Grant
Filed:
November 21, 2008
Date of Patent:
March 12, 2013
Assignee:
Allergan, Inc.
Inventors:
Dimitrios Stroumpoulis, Christopher S. Mudd, Ahmet Tezel
Abstract: The present invention provides an edible dosage form that incorporates optical elements (e.g., printed patterns, microrelief gratings, and/or macrorelief gratings), capable of producing unique optical effects and images in order to enable a user to better identify and differentiate the dosage forms, as well as to improve the detection of counterfeit production thereof, wherein the edible dosage forms may be made in a variety of ways to incorporate the optical elements therein.
Abstract: Compositions for treating alcohol hangover and methods of their use in treating or preventing hangover are described. The compositions include glycerophospholipids. Methods of use include administration or ingestion of the compositions after an episode of alcohol consumption. The compositions can be effective at preventing, eliminating, or reducing alcohol hangover when taken following an episode of alcohol consumption. In some embodiments, the glycerophospholipids are ingested with water or aqueous preparation, and some embodiments include B vitamins or other adjuvants.
Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
Type:
Grant
Filed:
March 9, 2011
Date of Patent:
February 19, 2013
Assignee:
Isis Pharmaceuticals, Inc
Inventors:
Michael T. Migawa, Xiaojing Wang, Eric E. Swayze, Richard H. Griffey
Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.
Abstract: The invention relates to the new usage of puerarin in the field of pharmaceutical products, in other words, it relates to the application of puerarin in the preparation of drugs for P2X3 mediated pain/nervous system diseases. The experiment shows that puerarin can inhibit pain-related behavioral responses, subsequently immunohistochemical analysis, in situ hybridization, RT-PCR, protein blotting and other techniques were utilized to observe the inhibition of puerarin on mRNA and protein expression of P2X3 receptor in dorsal root ganglion of rats with neuropathic pain and in dorsal root ganglion and sensory nerve ending in the burn model of rats, it was found by using whole-cell patch clamp technique that puerarin can significantly reduce the electric current activated by P2X3 receptor agonist in the neuron of dorsal root ganglion of rats with neuropathic pain.
Type:
Grant
Filed:
June 29, 2010
Date of Patent:
January 29, 2013
Assignee:
Nanchang University
Inventors:
Shangdong Liang, Changshui Xu, Yun Gao, Guilin Li, Jiari Lin, Shuangmei Liu, Han Liu, Jun Zhang, Xin Li